Results 161 to 170 of about 23,157 (220)

Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.

The Lancet HIV
BACKGROUND Although single-tablet, oral bictegravir, emtricitabine, and tenofovir alafenamide or dolutegravir and lamivudine are preferred regimens in several major guidelines and are widely used in many countries, they have not been compared in a fully ...
P. Ryan, J. L. Blanco, M. Masiá, L. García-Fraile, M. Crusells, Pere Domingo, Adrià Curran, Roberto Guerri-Fernandez, E. Bernal, J. Bravo, B. Revollo, J. Macías, J. Tiraboschi, R. Montejano, C. Amador, Miguel Torralba, D. Merino, V. Diaz-Brito, M. J. Galindo, Sergio Ferra, Aroa Villoslada, J. Losa, F. Fanjul, Xavier Perez-Stachowski, Joaquim Peraire, Joaquín Portilla, S. De la Fuente, Carlos Dueñas, M. Vázquez, Silvana Di Gregorio, H. Esteban, Pedro Gil, M. de Miguel, B. Alejos, Esteban Martínez   +34 more
semanticscholar   +1 more source

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Lancet, The, 2017
Paul Edward Sax, Anton Pozniak, Kirsten White   +2 more
exaly   +2 more sources

Novel RP-UPLC Method Development and Validation for Simultaneous Quantification of Emtricitabine, Tenofovir and Efavirenz in Bulk and Tablet Dosage Forms

Research Journal of Pharmacy and Technology, 2022
Objective: The objective of this work is to develop a precise, accurate and validated reverse phase ultra-performance liquid chromatographic technique for effective simultaneous determination of Emtricitabine, Tenofovir and Efavirenz in bulk and tablet ...
Sathish Kumar Konidala, R. Samineni, Yamarthi Venkateswara Rao, J. Chimakurthy, Chaitanya Sucharitha Kolakaluri, Vishali Korrapati   +5 more
semanticscholar   +1 more source

Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.

The Lancet HIV
BACKGROUND Doravirine and islatravir is an investigational, once-daily regimen with high antiviral potency, favourable safety and tolerability, and a low propensity for resistance.
A. Mills, Giuliano Rizzardini, M. Ramgopal, O. Osiyemi, J. Bogner, D. Hagins, R. Paredes, Jacques Reynes, Jürgen K. Rockstroh, Andrew Carr, Feng-Hsiu Su, Stephanie O Klopfer, Karen Eves, R. M. Plank, Todd Correll, Michelle C Fox   +15 more
semanticscholar   +1 more source

Electromimetic molecularly imprinted Polymersensor for wastewater emtricitabine.

Analytica Chimica Acta
BACKGROUND Emtricitabine (FTC) is a commonly prescribed anti-human immunodeficiency virus (HIV) drug that has been classified as an emerging environmental pharmaceutical micropollutant due to its poor metabolism, refractory nature to wastewater treatment,
K. V. Mokwebo, Samantha F. Douman, K. Januarie, Marlon Oranzie, N. Sanga, Z. Leve, Meleskow Cox, Natasha Ross, E. Iwuoha   +8 more
semanticscholar   +1 more source

Emtricitabine

Reactions Weekly, 2022
  +4 more sources

Tuning Diffusion Permeability of an Anti-Retroviral Drug, Emtricitabine, via Multicomponent Crystallizations

, 2021
Emtricitabine (ECB) is an anti-retroviral drug that inhibits HIV reverse transcriptase and prevents transcription of RNA to DNA. ECB exhibits high solubility and low permeability (log P < 0).
Vasanthi Palanisamy, Palash Sanphui, V. G. Jyothi, N. Shastri, G. Bolla, K. Palanisamy, M. Prakash, Venu R. Vangala   +7 more
semanticscholar   +1 more source

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

The Lancet HIV, 2019
BACKGROUND The single-tablet regimen consisting of bictegravir, emtricitabine, and tenofovir alafenamide is recommended for treatment of HIV-1 infection on the basis of data from 48 weeks of treatment.
H. Stellbrink, J. Arribas, J. L. Stephens, H. Albrecht, P. Sax, F. Maggiolo, C. Creticos, C. Martorell, Xuelian Wei, Rima K. Acosta, Sean E. Collins, D. Brainard, Hal Martin   +12 more
semanticscholar   +1 more source

Emtricitabine

Drugs, 2005
Emtricitabine (Emtriva) is an orally administered nucleoside reverse transcriptase inhibitor (NRTI) that is indicated in combination with other antiretroviral agents in the treatment of HIV infection in adults. As a component of antiretroviral therapy (ART), emtricitabine effectively reduces and/or maintains suppression of viral load in ART-naive ...
James E, Frampton, Caroline M, Perry
openaire   +2 more sources

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

The Lancet HIV, 2018
BACKGROUND Bictegravir, co-formulated with emtricitabine and tenofovir alafenamide, has shown good efficacy and tolerability, and similar bone, renal, and lipid profiles to dolutegravir, abacavir, and lamivudine, in treatment-naive adults with HIV-1 ...
J. Molina, D. Ward, I. Brar, A. Mills, H. Stellbrink, L. López-Cortés, P. Ruane, D. Podzamczer, C. Brinson, J. Custodio, Hui C. Liu, Kristen Andreatta, Hal Martin, A. Cheng, E. Quirk   +14 more
semanticscholar   +1 more source